Moreover, in CML patients in the accelerated phase/blastic phase (AP/BP), increased SP phenotype rather than ABCG2 expression was accompanied by the loss of PTEN protein and the up-regulation of p-Akt expression. The gene discussed is ABCG2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.